Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX STOCKHOLM  >  Better Collective A/S    BETCO   DK0060952240

BETTER COLLECTIVE A/S

(BETCO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AbbVie's Humira powers profit beat as COVID-19 weighs on Botox sales

share with twitter share with LinkedIn share with facebook
07/31/2020 | 10:47am EDT
A trader works by the post that trades AbbVie on the floor of the New York Stock Exchange

AbbVie Inc on Friday posted a quarterly adjusted profit above estimates as robust sales of its blockbuster arthritis treatment, Humira, helped cushion weak demand for its aesthetic drugs, including Botox, due to the COVID-19 pandemic.

The company bought Allergan for a hefty $63 billion in May, to gain control over its medical aesthetics business including lucrative wrinkle treatment Botox and reduce dependence on Humira ahead of its U.S. patent expiry in 2023.

The unit, however, suffered as Americans postponed non-emergency procedures during shelter-in-place restrictions to control the spread of the coronavirus.

Total Botox cosmetic comparable sales plunged 43.1% to $226 million and therapeutic sales fell 22.3% to $297 million in the second quarter ended June 30, on a comparable basis.

Mizuho analyst Vamil Divan said the aesthetics unit and Botox, however, are holding up better through COVID-19 than the brokerage had expected.

AbbVie said both the businesses are seeing a rapid recovery and are now performing near pre-COVID levels.

"At of the end of June, the vast majority of our aesthetics accounts have reopened in the United States, and we're seeing considerable pent-up demand," Chief Executive Officer Richard Gonzalez said on a post-earnings conference call.

The company also said it expects to see continued recovery in the second half of the year as its total business had already recovered to more than 90% of pre-COVID levels by the end of June.

AbbVie forecast a combined company 2020 adjusted earnings of $10.35 to $10.45 per share, representing a 11% annualized net accretion from the Allergan deal. The forecast includes the results of Allergan from May 8 through Dec. 31.

This is above consensus estimate of $10.35 per share, according to Divan.

Excluding items, AbbVie reported a quarterly profit of $2.34 per share, beating estimates of $2.19 per share, according to Refinitiv IBES data.

Share of the company were down 2% in late morning trading.

By Manojna Maddipatla and Mrinalika Roy


share with twitter share with LinkedIn share with facebook
All news about BETTER COLLECTIVE A/S
10/08BETTER COLLECTIVE A/S : nomination committee appointed
AQ
10/08Better Collective's nomination committee appointed
GL
10/01BETTER COLLECTIVE A/S : acquires Atemi Group for up to 44 million EUR
AQ
10/01Better Collective acquires Atemi Group for up to 44 million EUR
GL
09/30BETTER COLLECTIVE A/S : Change in number of shares and votes in Better Collectiv..
PU
09/30BETTER COLLECTIVE A/S : Change in number of shares and votes in Better Collectiv..
AQ
09/30Change in number of shares and votes in Better Collective A/S
GL
09/16BETTER COLLECTIVE A/S : Reporting of transactions made by persons discharging ma..
AQ
09/16Reporting of transactions made by persons discharging managerial responsibili..
GL
09/16BETTER COLLECTIVE A/S : The Majority shareholders of Better Collective have reso..
AQ
More news
Financials
Sales 2020 90,0 M 105 M 105 M
Net income 2020 19,0 M 22,1 M 22,1 M
Net Debt 2020 31,5 M 36,8 M 36,8 M
P/E ratio 2020 27,2x
Yield 2020 1,01%
Capitalization 505 M 589 M 590 M
EV / Sales 2020 5,97x
EV / Sales 2021 3,22x
Nbr of Employees 415
Free-Float 41,8%
Chart BETTER COLLECTIVE A/S
Duration : Period :
Better Collective A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BETTER COLLECTIVE A/S
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 2
Average target price 16,56 €
Last Close Price 10,95 €
Spread / Highest target 54,4%
Spread / Average Target 51,3%
Spread / Lowest Target 48,2%
EPS Revisions
Managers
NameTitle
Jesper Søgaard Chief Executive Officer
Jens Bager Chairman
Christian Dam Kirk Rasmussen Chief Operating Officer & Executive Vice President
Flemming Heise Pedersen Chief Financial Officer & Executive Vice President
Leif Nørgaard Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
BETTER COLLECTIVE A/S45.41%589
MICROSOFT CORPORATION29.82%1 547 785
ZOOM VIDEO COMMUNICATIONS, INC.619.69%139 275
SEA LIMITED315.27%81 462
ATLASSIAN CORPORATION PLC75.10%52 512
DASSAULT SYSTÈMES SE0.78%44 897